by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

Harbin Jixianglong Biotech Co., Ltd. Warning Letter Details

Warning Letter

Harbin Jixianglong Biotech Co., Ltd.

Recipient Title President and General Manager, Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street Hulan Qu Harbin Shi Heilongjiang Sheng , 150025 China

Issue DateMay 01, 2026

FEI Number3024038751

Violations1

CountryChina

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

CGMP/API/Adulterated and Misbranded Drugs

Harbin Jixianglong Biotech Co., Ltd. FDA Warning Letter, May 1, 2026